Please login to the form below

Not currently logged in
Email:
Password:

Xenazine

This page shows the latest Xenazine news and features for those working in and with pharma, biotech and healthcare.

FDA approves Teva's Huntington's disease drug at second attempt

FDA approves Teva's Huntington's disease drug at second attempt

The green light gives patients with HD in the US the first alternative to Lundbeck's already approved Xenazine (tetrabenazine) drug, which was launched onto the market in 2008. ... Sales of Xenazine slid by almost a third last year to $225m thanks to the

Latest news

  • FDA sets August review date for Teva's movement disorder drug FDA sets August review date for Teva's movement disorder drug

    Huntington's disease is a much smaller market than TD but that has not stopped the only approved drug for the condition - Lundbeck's Xenazine (tetrabenazine) - bring in sales of $330m

  • FDA turns down Teva's Huntington's disease drug FDA turns down Teva's Huntington's disease drug

    Teva's drug is a 'deuterated' form of VMAT-2 inhibitor tetrabenazine - the active ingredient in Lundbeck's already-approved Xenazine product - with a modified structure that seeks to improve the ... Xenazine is the only approved treatment for

  • Teva drug shows promise in movement disorder Teva drug shows promise in movement disorder

    While there is no FDA-approved drug for TD, the drug from which Teva's candidate is derived - Lundbeck's Xenazine (tetrabenazine) - has been used off-label to treat symptoms but

  • Teva starts M&A push with $3.5bn Auspex buy Teva starts M&A push with $3.5bn Auspex buy

    It is also relatively low risk, as the non-deuterated form of tetrabenazine is already sold as Xenazine by Lundbeck as a treatment for Huntington's and achieved sales of ... Moreover, it may also allow a quick route to market by referencing Xenazine data

  • Lundbeck still feeling effects from Cipralex patent loss Lundbeck still feeling effects from Cipralex patent loss

    Leading the upward trend was Xenazine (tetrabenazine) for the treatment of chorea associated with Huntington's disease - up 27% to 440m krone - and Onfi (clobazam) for Lennox-Gastaut syndrome which added

More from news
Approximately 1 fully matching, plus 11 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

4 ways to recruit Alzheimer’s disease patients for your clinical trial
What key things do you need to remember to reach patients living with Alzheimer’s disease?...
competitive intelligence
Integrating competitive intelligence into business development, licensing and M&A strategy
The advantages of partnering with a competitive intelligence or knowledge management team...
reaching HCPs during pandemic
Reaching patients and HCPs during the pandemic
COVID-19 has caused unprecedented disruption to drug launches, but some pharma companies avoided costly delays by quickly pivoting to digital channels...

Infographics